Last updated: February 17, 2026
Overview
NDC 00054-0084 corresponds to Rifaximin, a non-absorbable antibiotic prescribed for infections such as hepatic encephalopathy, travelers' diarrhea, and irritable bowel syndrome with diarrhea (IBS-D). The drug is marketed by Salix Pharmaceuticals, a subsidiary of Ipsen, and has a substantial market share constrained by competition and patent status.
Market Size and Trends
Market Value (2022): Estimated at $600 million globally, driven by increasing indications and expanding patient populations.
Growth Rate: Compound annual growth rate (CAGR) of approximately 5% anticipated from 2023 to 2027, reflecting rising prevalence of gastrointestinal disorders and expanded indications.
Key Market Players:
- Salix Pharmaceuticals (Ipsen)
- Ferring Pharmaceuticals (Ferring is developing generic formulations)
- Generics manufacturers (pending patent expirations)
Indications and Competition
Primary Uses:
- Hepatic encephalopathy (HE)
- Travelers' diarrhea
- IBS-D
Patents:
- Original patents expired in the US in 2020, leading to increased generic entry.
- Pending or granted patents in some markets may restrict immediate competition.
Generic Competition Impact:
- Generics have entered the US market following patent expiry, leading to price erosion.
- Current generic prices are approximately 40-60% lower than branded prices.
Pricing Analysis
Branded Rifaximin (Brand: Xifaxan):
- Typical retail price per 550 mg tablet: $57-$70
- Monthly treatment cost (for HE, 550 mg three times/day): approximately $5,100-$6,300
Generic Rifaximin:
- Price per tablet: $15-$30
- Monthly treatment cost: approximately $1,350-$2,700
Insurance Impact:
- Payers favor generics; patient co-pays are substantially lower for generics.
- Reimbursement rates are aligned with wholesale acquisition costs (WAC), affecting net revenues.
Price Projections (2023-2027)
| Year |
Estimated Average Price per 550 mg Tablet |
Key Factors |
| 2023 |
$35 |
Increased generic market penetration |
| 2024 |
$30 |
Further generic competition, price pressure |
| 2025 |
$25 |
Market stabilization with established generics |
| 2026 |
$20 |
Potential biosimilar or new formulation entry |
| 2027 |
$15 |
Market saturation, price consolidation |
Note: All projections assume continued patent expiry effects and no new branded formulations or indications.
Regulatory and Patent Outlook
- US patent expiry for Rifaximin was in 2020.
- Patent challenges and biosimilar development could influence prices.
- Some markets may retain exclusivity through formulation patents or new indications.
Key Challenges
- Price erosion driven by generics.
- Competitive landscape shifting toward biosimilars and novel formulations.
- Variability in reimbursement and formulary placement.
Investment and R&D Implications
- Price decreases and market saturation suggest limited revenue growth for branded formulations.
- Focus on niche indications or combination therapies may present opportunities.
- Companies investing in biosimilars or innovative delivery methods could shift market shares.
Key Takeaways
- The global market for Rifaximin (NDC 00054-0084) is ~$600 million, expected to grow at 5% CAGR through 2027.
- Patent expirations since 2020 have led to extensive generic competition, pressuring prices.
- Branded prices range from $57 to $70 per tablet; generics are priced between $15 and $30.
- Price projections decline from $35 to $15 per tablet over five years, influenced by generic and biosimilar competition.
- Market dynamics favor cost reductions in the near term; innovation or new indications could alter these trends.
FAQs
1. What are the main indications for Rifaximin?
Primarily used for hepatic encephalopathy, travelers' diarrhea, and IBS-D.
2. How has patent expiration affected the market?
Patent expiry in 2020 led to generic entry, causing significant price reductions and increased market competition.
3. What is the projected price trend for Rifaximin?
Prices are expected to decline from approximately $35 per tablet in 2023 to around $15 by 2027.
4. Who are the leading competitors?
Generic manufacturers and biosimilar developers, with Salix/Ipsen maintaining market share for branded formulations.
5. What opportunities exist for future growth?
Innovation in formulations, new indications, or combination therapies may enable differentiation beyond declining prices.
References
- IQVIA. (2022). Pharmaceutical Market Analysis.
- FDB. (2022). Drug Pricing Trends.
- Ipsen Pharmaceuticals. (2022). Xifaxan Product Data.
- US Patent and Trademark Office. (2020). Patent expiry information.
- EvaluatePharma. (2022). Global Gastrointestinal Market Reports.
